Year |
Citation |
Score |
2020 |
Kouwenhoven WM, Fortin G, Penttinen AM, Florence C, Delignat-Lavaud B, Bourque MJ, Trimbuch T, Luppi MP, Salvail-Lacoste A, Legault P, Poulin JF, Rosenmund C, Awatramani R, Trudeau LÉ. VGLUT2 EXPRESSION IN DOPAMINE NEURONS CONTRIBUTES TO POST-LESIONAL STRIATAL REINNERVATION. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 32928885 DOI: 10.1523/Jneurosci.0823-20.2020 |
0.572 |
|
2020 |
Anilkumar U, Khacho M, Cuillerier A, Harris R, Patten DA, Bilen M, Iqbal MA, Guo DY, Trudeau LE, Park DS, Harper ME, Burelle Y, Slack RS. MCL-1 maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions. Cell Death & Disease. 11: 321. PMID 32371858 DOI: 10.1038/S41419-020-2498-9 |
0.345 |
|
2019 |
Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31483900 DOI: 10.1002/Mds.27823 |
0.473 |
|
2019 |
Giguère N, Delignat-Lavaud B, Herborg F, Voisin A, Li Y, Jacquemet V, Anand-Srivastava M, Gether U, Giros B, Trudeau LÉ. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. Plos Genetics. 15: e1008352. PMID 31449520 DOI: 10.1371/Journal.Pgen.1008352 |
0.547 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, et al. Intestinal infection triggers Parkinson's disease-like symptoms in Pink1 mice. Nature. PMID 31316206 DOI: 10.1038/S41586-019-1405-Y |
0.782 |
|
2019 |
Zhu H, Lussier F, Ducrot C, Bourque MJ, Spatz JP, Cui W, Yu L, Peng W, Trudeau LE, Bazuin CG, Masson JF. Block copolymer brush layer-templated gold nanoparticles on nanofibers for surface-enhanced Raman scattering optophysiology. Acs Applied Materials & Interfaces. PMID 30615826 DOI: 10.1021/Acsami.8B19161 |
0.754 |
|
2019 |
Tritsch N, Castillo PE, Trudeau L. Decision letter: RIM is essential for stimulated but not spontaneous somatodendritic dopamine release in the midbrain Elife. DOI: 10.7554/Elife.47972.011 |
0.422 |
|
2018 |
Trudeau LE, El Mestikawy S. Glutamate Cotransmission in Cholinergic, GABAergic and Monoamine Systems: Contrasts and Commonalities. Frontiers in Neural Circuits. 12: 113. PMID 30618649 DOI: 10.3389/Fncir.2018.00113 |
0.372 |
|
2018 |
Trudeau LE, El Mestikawy S. Glutamate Cotransmission in Cholinergic, GABAergic and Monoamine Systems: Contrasts and Commonalities. Frontiers in Neural Circuits. 12: 113. PMID 30618649 DOI: 10.3389/Fncir.2018.00113 |
0.372 |
|
2018 |
Fortin GM, Ducrot C, Giguère N, Kouwenhoven WM, Bourque MJ, Pacelli C, Varaschin RK, Brill M, Singh S, Wiseman PW, Trudeau LÉ. Segregation of dopamine and glutamate release sites in dopamine neuron axons: regulation by striatal target cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201800713RR. PMID 30011230 DOI: 10.1096/Fj.201800713Rr |
0.842 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau LE. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. Frontiers in Neurology. 9: 455. PMID 29971039 DOI: 10.3389/fneur.2018.00455 |
0.311 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau LE. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. Frontiers in Neurology. 9: 455. PMID 29971039 DOI: 10.3389/Fneur.2018.00455 |
0.425 |
|
2018 |
Giguere N, Pacelli C, Saumure C, Bourque MJ, Matheoud D, Levesque D, Slack RS, Park DS, Trudeau LE. Comparative analysis of Parkinson's disease-associated genes reveals altered survival and bioenergetics of parkin-deficient dopamine neurons in mice. The Journal of Biological Chemistry. PMID 29700116 DOI: 10.1074/Jbc.Ra117.000499 |
0.77 |
|
2018 |
Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. Neurobiology of Disease. PMID 29571591 DOI: 10.1016/J.Nbd.2018.02.018 |
0.377 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2018 |
Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE. Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. PMID 29374538 DOI: 10.1016/J.Neuroscience.2018.01.027 |
0.825 |
|
2017 |
Lussier F, Brulé T, Bourque MJ, Ducrot C, Trudeau LÉ, Masson JF. Dynamic SERS nanosensor for neurotransmitter sensing near neurons. Faraday Discussions. PMID 28895964 DOI: 10.1039/C7Fd00131B |
0.817 |
|
2017 |
Lussier F, Brulé T, Bourque MJ, Ducrot C, Trudeau LÉ, Masson JF. Dynamic SERS nanosensor for neurotransmitter sensing near neurons. Faraday Discussions. PMID 28895964 DOI: 10.1039/C7Fd00131B |
0.817 |
|
2017 |
Hryhorczuk C, Sheng Z, Décarie-Spain L, Giguère N, Ducrot C, Trudeau LÉ, Routh V, Alquier T, Fulton S. Oleic Acid in the Ventral Tegmental Area Inhibits Feeding, Food Reward and Dopamine Tone. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 28857071 DOI: 10.1038/Npp.2017.203 |
0.807 |
|
2017 |
Arathoon LR, Gleave JA, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism. Neurobiology of Disease. PMID 28673739 DOI: 10.1016/J.Nbd.2017.06.009 |
0.411 |
|
2017 |
Ramet L, Zimmermann J, Bersot T, Poirel O, De Gois S, Silm K, Yae Sakae D, Mansouri-Guilani N, Bourque MJ, Trudeau LE, Pietrancosta N, Daumas S, Bernard V, Rosenmund C, El Mestikawy S. Characterization of a human point mutation of VGLUT3 (p.A211V) in the rodent brain suggests a non-uniform distribution of the transporter in synaptic vesicles. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 28314816 DOI: 10.1523/Jneurosci.0282-16.2017 |
0.361 |
|
2016 |
Doucet-Beaupré H, Gilbert C, Profes MS, Chabrat A, Pacelli C, Giguère N, Rioux V, Charest J, Deng Q, Laguna A, Ericson J, Perlmann T, Ang SL, Cicchetti F, Parent M, ... Trudeau LE, et al. Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. Proceedings of the National Academy of Sciences of the United States of America. PMID 27407143 DOI: 10.1073/Pnas.1520387113 |
0.733 |
|
2016 |
Voisin AN, Mnie-Filali O, Giguère N, Fortin GM, Vigneault E, El Mestikawy S, Descarries L, Trudeau LÉ. Axonal Segregation and Role of the Vesicular Glutamate Transporter VGLUT3 in Serotonin Neurons. Frontiers in Neuroanatomy. 10: 39. PMID 27147980 DOI: 10.3389/Fnana.2016.00039 |
0.316 |
|
2016 |
Voisin AN, Mnie-Filali O, Giguère N, Fortin GM, Vigneault E, El Mestikawy S, Descarries L, Trudeau LÉ. Axonal Segregation and Role of the Vesicular Glutamate Transporter VGLUT3 in Serotonin Neurons. Frontiers in Neuroanatomy. 10: 39. PMID 27147980 DOI: 10.3389/Fnana.2016.00039 |
0.316 |
|
2016 |
Voisin AN, Mnie-Filali O, Giguère N, Fortin GM, Vigneault E, El Mestikawy S, Descarries L, Trudeau LÉ. Axonal Segregation and Role of the Vesicular Glutamate Transporter VGLUT3 in Serotonin Neurons. Frontiers in Neuroanatomy. 10: 39. PMID 27147980 DOI: 10.3389/Fnana.2016.00039 |
0.316 |
|
2016 |
Voisin AN, Mnie-Filali O, Giguère N, Fortin GM, Vigneault E, El Mestikawy S, Descarries L, Trudeau LÉ. Axonal Segregation and Role of the Vesicular Glutamate Transporter VGLUT3 in Serotonin Neurons. Frontiers in Neuroanatomy. 10: 39. PMID 27147980 DOI: 10.3389/Fnana.2016.00039 |
0.316 |
|
2016 |
Voisin AN, Mnie-Filali O, Giguère N, Fortin GM, Vigneault E, El Mestikawy S, Descarries L, Trudeau LÉ. Axonal Segregation and Role of the Vesicular Glutamate Transporter VGLUT3 in Serotonin Neurons. Frontiers in Neuroanatomy. 10: 39. PMID 27147980 DOI: 10.3389/Fnana.2016.00039 |
0.316 |
|
2016 |
Selleri S, Bifsha P, Civini S, Pacelli C, Dieng MM, Lemieux W, Jin P, Bazin R, Patey N, Marincola FM, Moldovan F, Zaouter C, Trudeau LE, Benabdhalla B, Louis I, et al. Human mesenchymal stromal cell-secreted lactate induces M2-macrophage differentiation by metabolic reprogramming. Oncotarget. PMID 27070086 DOI: 10.18632/Oncotarget.8623 |
0.648 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2016 |
Trudeau L. Axonal arborization and energetic metabolism of nigral dopamine neurons: a window into selective vulnerability in Parkinson’s disease Intrinsic Activity. 4: A9.1. DOI: 10.25006/IA.4.S2-A9.1 |
0.353 |
|
2015 |
Ng E, Varaschin RK, Su P, Browne CJ, Hermainski J, Foll BL, Pongs O, Liu F, Trudeau LE, Roder JC, Wong AH. Neuronal calcium sensor-1 deletion in the mouse decreases motivation and dopamine release in the nucleus accumbens. Behavioural Brain Research. PMID 26738968 DOI: 10.1016/J.Bbr.2015.12.037 |
0.506 |
|
2015 |
Samuel F, Flavin WP, Iqbal S, Pacelli C, Sri Renganathan SD, Trudeau LE, Campbell EM, Fraser PE, Tandon A. Effects of Serine 129 phosphorylation on α-synuclein aggregation, membrane association, and internalization. The Journal of Biological Chemistry. PMID 26719332 DOI: 10.1074/Jbc.M115.705095 |
0.667 |
|
2015 |
Pacelli C, Giguère N, Bourque MJ, Lévesque M, Slack RS, Trudeau LÉ. Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. Current Biology : Cb. 25: 2349-60. PMID 26320949 DOI: 10.1016/J.Cub.2015.07.050 |
0.75 |
|
2015 |
Apuschkin M, Stilling S, Rahbek-Clemmensen T, Sørensen G, Fortin G, Herborg Hansen F, Eriksen J, Trudeau LE, Egerod K, Gether U, Rickhag M. A novel dopamine transporter transgenic mouse line for identification and purification of midbrain dopaminergic neurons reveals midbrain heterogeneity. The European Journal of Neuroscience. 42: 2438-54. PMID 26286107 DOI: 10.1111/Ejn.13046 |
0.509 |
|
2015 |
Thibault D, Giguère N, Loustalot F, Bourque MJ, Ducrot C, El Mestikawy S, Trudeau LÉ. Homeostatic regulation of excitatory synapses on striatal medium spiny neurons expressing the D2 dopamine receptor. Brain Structure & Function. PMID 25782435 DOI: 10.1007/S00429-015-1029-4 |
0.841 |
|
2014 |
Trudeau LE, Hnasko TS, Wallén-Mackenzie A, Morales M, Rayport S, Sulzer D. The multilingual nature of dopamine neurons. Progress in Brain Research. 211: 141-64. PMID 24968779 DOI: 10.1016/B978-0-444-63425-2.00006-4 |
0.591 |
|
2014 |
Sanchez G, Varaschin RK, Büeler H, Marcogliese PC, Park DS, Trudeau LE. Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. Plos One. 9: e94826. PMID 24733019 DOI: 10.1371/Journal.Pone.0094826 |
0.502 |
|
2014 |
Charfi I, Nagi K, Mnie-Filali O, Thibault D, Balboni G, Schiller PW, Trudeau LE, Pineyro G. Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists Cellular and Molecular Life Sciences. 71: 1529-1546. PMID 24022593 DOI: 10.1007/S00018-013-1461-7 |
0.632 |
|
2013 |
Thibault D, Loustalot F, Fortin GM, Bourque MJ, Trudeau LÉ. Evaluation of D1 and D2 dopamine receptor segregation in the developing striatum using BAC transgenic mice. Plos One. 8: e67219. PMID 23843993 DOI: 10.1371/Journal.Pone.0067219 |
0.672 |
|
2013 |
Fasano C, Bourque MJ, Lapointe G, Leo D, Thibault D, Haber M, Kortleven C, Desgroseillers L, Murai KK, Trudeau LÉ. Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology. 67: 432-43. PMID 23231809 DOI: 10.1016/J.Neuropharm.2012.11.030 |
0.847 |
|
2012 |
Hernandez-Baltazar D, Martinez-Fong D, Trudeau LE. Optimizing NTS-Polyplex as a Tool for Gene Transfer to Cultured Dopamine Neurons Plos One. 7. PMID 23300540 DOI: 10.1371/Journal.Pone.0051341 |
0.517 |
|
2012 |
Fortin GM, Bourque MJ, Mendez JA, Leo D, Nordenankar K, Birgner C, Arvidsson E, Rymar VV, Bérubé-Carrière N, Claveau AM, Descarries L, Sadikot AF, Wallén-Mackenzie Å, Trudeau LÉ. Glutamate corelease promotes growth and survival of midbrain dopamine neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 17477-91. PMID 23197738 DOI: 10.1523/Jneurosci.1939-12.2012 |
0.76 |
|
2012 |
Kortleven C, Bruneau LC, Trudeau LE. Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. Neuropharmacology. 63: 983-991. PMID 22884466 DOI: 10.1016/J.Neuropharm.2012.07.037 |
0.841 |
|
2012 |
Martinez-Fong D, Bannon MJ, Trudeau LE, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, Reyes-Corona D, Armendáriz-Borunda J, Navarro-Quiroga I. NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 1052-69. PMID 22406187 DOI: 10.1016/j.nano.2012.02.009 |
0.311 |
|
2012 |
Bérubé-Carrière N, Guay G, Fortin GM, Kullander K, Olson L, Wallén-Mackenzie Å, Trudeau LE, Descarries L. Ultrastructural characterization of the mesostriatal dopamine innervation in mice, including two mouse lines of conditional VGLUT2 knockout in dopamine neurons. The European Journal of Neuroscience. 35: 527-38. PMID 22330100 DOI: 10.1111/J.1460-9568.2012.07992.X |
0.539 |
|
2012 |
Bérubé-Carrière N, Guay F, Fortin GM, Kullander K, Olson L, Wallén-Mackenzie A, Trudeau LE, Descarries L. Ultrastructural characterization of the mesostriatal dopamine innervations in mice, including two mouse lines of conditional VGLUT2 knockout in dopamine neurons European Journal of Neuroscience. 36: 2567-2570. DOI: 10.1111/j.1460-9568.2012.08110.x |
0.392 |
|
2012 |
MacDonald R, Trudeau L, Chalifour L, Paudel H. Transcriptional suppression of agrin promotes Alzheimer's-like synaptic and neurovascular pathology in primary neurons in culture and mouse brain Alzheimers & Dementia. 8: 649. DOI: 10.1016/J.Jalz.2012.05.1739 |
0.398 |
|
2011 |
Alsiö J, Nordenankar K, Arvidsson E, Birgner C, Mahmoudi S, Halbout B, Smith C, Fortin GM, Olson L, Descarries L, Trudeau LÉ, Kullander K, Lévesque D, Wallén-Mackenzie A. Enhanced sucrose and cocaine self-administration and cue-induced drug seeking after loss of VGLUT2 in midbrain dopamine neurons in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 12593-603. PMID 21880920 DOI: 10.1523/Jneurosci.2397-11.2011 |
0.483 |
|
2011 |
Martel P, Leo D, Fulton S, Bérard M, Trudeau LE. Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function. Plos One. 6: e20402. PMID 21647367 DOI: 10.1371/Journal.Pone.0020402 |
0.639 |
|
2011 |
Mendez JA, Bourque MJ, Fasano C, Kortleven C, Trudeau LE. Somatodendritic dopamine release requires synaptotagmin 4 and 7 and the participation of voltage-gated calcium channels. The Journal of Biological Chemistry. 286: 23928-37. PMID 21576241 DOI: 10.1074/Jbc.M111.218032 |
0.81 |
|
2011 |
El Mestikawy S, Wallén-Mackenzie A, Fortin GM, Descarries L, Trudeau LE. From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Nature Reviews. Neuroscience. 12: 204-16. PMID 21415847 DOI: 10.1038/Nrn2969 |
0.451 |
|
2011 |
Kortleven C, Fasano C, Thibault D, Lacaille JC, Trudeau LE. The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice. The European Journal of Neuroscience. 33: 1751-60. PMID 21410793 DOI: 10.1111/J.1460-9568.2011.07648.X |
0.838 |
|
2011 |
Thibault D, Albert PR, Pineyro G, Trudeau LÉ. Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism. The Journal of Biological Chemistry. 286: 9174-84. PMID 21233215 DOI: 10.1074/Jbc.M110.166454 |
0.688 |
|
2011 |
Fulton S, Thibault D, Mendez JA, Lahaie N, Tirotta E, Borrelli E, Bouvier M, Tempel BL, Trudeau LE. Contribution of Kv1.2 voltage-gated potassium channel to D2 autoreceptor regulation of axonal dopamine overflow. The Journal of Biological Chemistry. 286: 9360-72. PMID 21233214 DOI: 10.1074/Jbc.M110.153262 |
0.802 |
|
2011 |
Drouin-Ouellet J, Brownell AL, Saint-Pierre M, Fasano C, Emond V, Trudeau LE, Lévesque D, Cicchetti F. Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia. 59: 188-99. PMID 21125661 DOI: 10.1002/Glia.21086 |
0.338 |
|
2010 |
Fasano C, Kortleven C, Trudeau LE. Chronic activation of the D2 autoreceptor inhibits both glutamate and dopamine synapse formation and alters the intrinsic properties of mesencephalic dopamine neurons in vitro. The European Journal of Neuroscience. 32: 1433-41. PMID 20846243 DOI: 10.1111/J.1460-9568.2010.07397.X |
0.856 |
|
2010 |
Xu B, Goldman JS, Rymar VV, Forget C, Lo PS, Bull SJ, Vereker E, Barker PA, Trudeau LE, Sadikot AF, Kennedy TE. Critical roles for the netrin receptor deleted in colorectal cancer in dopaminergic neuronal precursor migration, axon guidance, and axon arborization. Neuroscience. 169: 932-49. PMID 20493932 DOI: 10.1016/J.Neuroscience.2010.05.025 |
0.411 |
|
2010 |
Thibault D, Kortleven C, Fasano C, Dal Bo G, Trudeau LE. [Recent discoveries on the function and plasticity of central dopamine pathways]. Mã©Decine Sciences : M/S. 26: 165-70. PMID 20188048 DOI: 10.1051/Medsci/2010262165 |
0.831 |
|
2010 |
Birgner C, Nordenankar K, Lundblad M, Mendez JA, Smith C, le Grevès M, Galter D, Olson L, Fredriksson A, Trudeau LE, Kullander K, Wallén-Mackenzie A. VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. Proceedings of the National Academy of Sciences of the United States of America. 107: 389-94. PMID 20018672 DOI: 10.1073/Pnas.0910986107 |
0.736 |
|
2009 |
Bérubé-Carrière N, Riad M, Dal Bo G, Lévesque D, Trudeau LE, Descarries L. The dual dopamine-glutamate phenotype of growing mesencephalic neurons regresses in mature rat brain. The Journal of Comparative Neurology. 517: 873-91. PMID 19844994 DOI: 10.1002/Cne.22194 |
0.443 |
|
2009 |
Fawaz CS, Martel P, Leo D, Trudeau LE. Presynaptic action of neurotensin on dopamine release through inhibition of D2 receptor function Bmc Neuroscience. 10: 96. PMID 19682375 DOI: 10.1186/1471-2202-10-96 |
0.483 |
|
2008 |
Fasano C, Poirier A, DesGroseillers L, Trudeau LE. Chronic activation of the D2 dopamine autoreceptor inhibits synaptogenesis in mesencephalic dopaminergic neurons in vitro. The European Journal of Neuroscience. 28: 1480-90. PMID 18973573 DOI: 10.1111/J.1460-9568.2008.06450.X |
0.478 |
|
2008 |
Dal Bo G, Bérubé-Carrière N, Mendez JA, Leo D, Riad M, Descarries L, Lévesque D, Trudeau LE. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion. Neuroscience. 156: 59-70. PMID 18706980 DOI: 10.1016/J.Neuroscience.2008.07.032 |
0.696 |
|
2008 |
Fasano C, Thibault D, Trudeau LE. Culture of postnatal mesencephalic dopamine neurons on an astrocyte monolayer. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 3.21. PMID 18633997 DOI: 10.1002/0471142301.Ns0321S44 |
0.73 |
|
2008 |
Mendez JA, Bourque MJ, Dal Bo G, Bourdeau ML, Danik M, Williams S, Lacaille JC, Trudeau LE. Developmental and target-dependent regulation of vesicular glutamate transporter expression by dopamine neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 6309-18. PMID 18562601 DOI: 10.1523/Jneurosci.1331-08.2008 |
0.75 |
|
2008 |
Huh CY, Danik M, Manseau F, Trudeau LE, Williams S. Chronic exposure to nerve growth factor increases acetylcholine and glutamate release from cholinergic neurons of the rat medial septum and diagonal band of Broca via mechanisms mediated by p75NTR. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 1404-9. PMID 18256260 DOI: 10.1523/Jneurosci.4851-07.2008 |
0.486 |
|
2008 |
Descarries L, Bérubé-Carrière N, Riad M, Bo GD, Mendez JA, Trudeau LE. Glutamate in dopamine neurons: synaptic versus diffuse transmission. Brain Research Reviews. 58: 290-302. PMID 18042492 DOI: 10.1016/J.Brainresrev.2007.10.005 |
0.756 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805Ar |
0.316 |
|
2008 |
Sulzer D, Trudeau LE, Rayport S. Postnatally Derived Ventral Midbrain Dopamine Neuron Cultures as a Model System for Studying Neurotoxicity and Parkinson's Disease Parkinson's Disease. 491-504. DOI: 10.1016/B978-0-12-374028-1.00037-3 |
0.398 |
|
2007 |
Trudeau LE, Gutiérrez R. On cotransmission & neurotransmitter phenotype plasticity. Molecular Interventions. 7: 138-46. PMID 17609520 DOI: 10.1124/Mi.7.3.5 |
0.518 |
|
2006 |
Jomphe C, Lemelin PL, Okano H, Kobayashi K, Trudeau LE. Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons European Journal of Neuroscience. 24: 2789-2800. PMID 17116165 DOI: 10.1111/J.1460-9568.2006.05151.X |
0.507 |
|
2006 |
Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-MartÃnez V, Flores G, Navarro-Quiroga I, Trudeau LE, Aceves J, Martinez-Arguelles DB, Garcia-Villegas R, Jiménez I, Segovia J, Martinez-Fong D. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 857-65. PMID 17015039 DOI: 10.1016/J.Ymthe.2006.09.001 |
0.39 |
|
2006 |
Pontier SM, Lahaie N, Ginham R, St-Gelais F, Bonin H, Bell DJ, Flynn H, Trudeau LE, McIlhinney J, White JH, Bouvier M. Coordinated action of NSF and PKC regulates GABAB receptor signaling efficacy. The Embo Journal. 25: 2698-709. PMID 16724110 DOI: 10.1038/Sj.Emboj.7601157 |
0.387 |
|
2006 |
Fortin GD, Desrosiers CC, Yamaguchi N, Trudeau LE. Basal somatodendritic dopamine release requires snare proteins. Journal of Neurochemistry. 96: 1740-9. PMID 16539689 DOI: 10.1111/J.1471-4159.2006.03699.X |
0.527 |
|
2006 |
Forget C, Stewart J, Trudeau LE. Impact of basic FGF expression in astrocytes on dopamine neuron synaptic function and development. The European Journal of Neuroscience. 23: 608-16. PMID 16487142 DOI: 10.1111/J.1460-9568.2006.04570.X |
0.553 |
|
2006 |
Jomphe C, Tiberi M, Trudeau LE. Expression of D2 receptor isoforms in cultured neurons reveals equipotent autoreceptor function Neuropharmacology. 50: 595-605. PMID 16412480 DOI: 10.1016/J.Neuropharm.2005.11.010 |
0.467 |
|
2005 |
Dal Bo G, Trudeau LE. Serotonin in dopamine neurons? An interesting hypothesis about the mechanism of action of antidepressants with a feeling of « déjà-vu »... | De la sérotonine dans les neurones à dopamine? Une hypothèse intéressante sur le mode d'action des antidépresseurs, avec un sentiment de « déjà-vu ».. Medecine/Sciences. 21: 589-590. PMID 15985199 DOI: 10.1051/Medsci/2005216-7589 |
0.469 |
|
2005 |
Jomphe C, Bourque MJ, Fortin GD, St-Gelais F, Okano H, Kobayashi K, Trudeau LE. Use of TH-EGFP transgenic mice as a source of identified dopaminergic neurons for physiological studies in postnatal cell culture. Journal of Neuroscience Methods. 146: 1-12. PMID 15935217 DOI: 10.1016/J.Jneumeth.2005.01.014 |
0.387 |
|
2005 |
Michel FJ, Fortin GD, Martel P, Yeomans J, Trudeau LE. M3-like muscarinic receptors mediate Ca2+ influx in rat mesencephalic GABAergic neurones through a protein kinase C-dependent mechanism. Neuropharmacology. 48: 796-809. PMID 15829252 DOI: 10.1016/J.Neuropharm.2005.01.006 |
0.652 |
|
2005 |
Croft BG, Fortin GD, Corera AT, Edwards RH, Beaudet A, Trudeau LE, Fon EA. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice. Molecular Biology of the Cell. 16: 306-15. PMID 15496457 DOI: 10.1091/Mbc.E04-07-0559 |
0.527 |
|
2004 |
Trudeau LE. Glutamate co-transmission as an emerging concept in monoamine neuron function Journal of Psychiatry and Neuroscience. 29: 296-310. PMID 15309046 |
0.446 |
|
2004 |
St-Gelais F, Ménard C, Congar P, Trudeau LE, Massicotte G. Postsynaptic injection of calcium-independent phospholipase A2 inhibitors selectively increases AMPA receptor-mediated synaptic transmission. Hippocampus. 14: 319-25. PMID 15132431 DOI: 10.1002/Hipo.10176 |
0.71 |
|
2004 |
St-Gelais F, Legault M, Bourque MJ, Rompré PP, Trudeau LE. Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 2566-74. PMID 15014132 DOI: 10.1523/Jneurosci.5376-03.2004 |
0.472 |
|
2004 |
Dal Bo G, St-Gelais F, Danik M, Williams S, Cotton M, Trudeau LE. Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine. Journal of Neurochemistry. 88: 1398-405. PMID 15009640 DOI: 10.1046/J.1471-4159.2003.02277.X |
0.584 |
|
2004 |
Michel FJ, Robillard JM, Trudeau LE. Regulation of rat mesencephalic GABAergic neurones through muscarinic receptors. The Journal of Physiology. 556: 429-45. PMID 14766941 DOI: 10.1113/Jphysiol.2003.057737 |
0.692 |
|
2003 |
Jomphe C, Lévesque D, Trudeau LE. Calcium-dependent, D2 receptor-independent induction of c-fos by haloperidol in dopamine neurons Naunyn-Schmiedeberg's Archives of Pharmacology. 367: 480-489. PMID 12695877 DOI: 10.1007/s00210-003-0742-3 |
0.39 |
|
2002 |
Congar P, Trudeau LE. Perturbation of synaptic vesicle delivery during neurotransmitter release triggered independently of calcium influx Journal of Physiology. 542: 779-793. PMID 12154178 DOI: 10.1113/Jphysiol.2002.020222 |
0.721 |
|
2002 |
Bergevin A, Girardot D, Bourque MJ, Trudeau LE. Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons. Neuropharmacology. 42: 1065-78. PMID 12128008 DOI: 10.1016/S0028-3908(02)00061-8 |
0.441 |
|
2002 |
Legault M, Congar P, Michel FJ, Trudeau LE. Presynaptic action of neurotensin on cultured ventral tegmental area dopaminergic neurones Neuroscience. 111: 177-187. PMID 11955721 DOI: 10.1016/S0306-4522(01)00614-5 |
0.82 |
|
2002 |
Congar P, Bergevin A, Trudeau LE. D2 receptors inhibit the secretory process downstream from calcium influx in dopaminergic neurons: Implication of K+ channels Journal of Neurophysiology. 87: 1046-1056. PMID 11826068 DOI: 10.1152/Jn.00459.2001 |
0.775 |
|
2000 |
Bourque MJ, Trudeau LE. GDNF enhances the synaptic efficacy of dopaminergic neurons in culture. The European Journal of Neuroscience. 12: 3172-80. PMID 10998101 DOI: 10.1046/J.1460-9568.2000.00219.X |
0.574 |
|
2000 |
Michel FJ, Trudeau LE. Clozapine inhibits synaptic transmission at GABAergic synapses established by ventral tegmental area neurones in culture Neuropharmacology. 39: 1536-1543. PMID 10854898 DOI: 10.1016/S0028-3908(99)00239-7 |
0.558 |
|
1999 |
Trudeau LE, Parpura V, Haydon PG. Activation of neurotransmitter release in hippocampal nerve terminals during recovery from intracellular acidification. Journal of Neurophysiology. 81: 2627-35. PMID 10368383 DOI: 10.1152/Jn.1999.81.6.2627 |
0.587 |
|
1998 |
Trudeau LE, Fang Y, Haydon PG. Modulation of an early step in the secretory machinery in hippocampal nerve terminals. Proceedings of the National Academy of Sciences of the United States of America. 95: 7163-8. PMID 9618556 DOI: 10.1073/pnas.95.12.7163 |
0.562 |
|
1998 |
Bahls FH, Lartius R, Trudeau LE, Doyle RT, Fang Y, Witcher D, Campbell K, Haydon PG. Contact-dependent regulation of N-type calcium channel subunits during synaptogenesis. Journal of Neurobiology. 35: 198-208. PMID 9581974 DOI: 10.1002/(Sici)1097-4695(199805)35:2<198::Aid-Neu6>3.0.Co;2-# |
0.732 |
|
1998 |
Haydon PG, Trudeau LE. Regulatory roles for GTP-binding proteins in nerve terminals Seminars in Neuroscience. 9: 220-231. DOI: 10.1006/Smns.1997.0120 |
0.544 |
|
1996 |
Trudeau LE, Emery DG, Haydon PG. Direct modulation of the secretory machinery underlies PKA-dependent synaptic facilitation in hippocampal neurons. Neuron. 17: 789-97. PMID 8893035 DOI: 10.1016/S0896-6273(00)80210-X |
0.635 |
|
1996 |
Trudeau LE, Doyle RT, Emery DG, Haydon PG. Calcium-independent activation of the secretory apparatus by ruthenium red in hippocampal neurons: a new tool to assess modulation of presynaptic function. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 46-54. PMID 8613808 DOI: 10.1523/Jneurosci.16-01-00046.1996 |
0.773 |
|
1995 |
Trudeau LE, Castellucci VF. Postsynaptic modifications in long-term facilitation in Aplysia: Upregulation of excitatory amino acid receptors Journal of Neuroscience. 15: 1275-1284. PMID 7869098 DOI: 10.1523/Jneurosci.15-02-01275.1995 |
0.639 |
|
1993 |
Trudeau LE, Castellucci VF. Functional uncoupling of inhibitory interneurons plays an important role in short-term sensitization of Aplysia gill and siphon withdrawal reflex Journal of Neuroscience. 13: 2126-2135. PMID 8478692 DOI: 10.1523/Jneurosci.13-05-02126.1993 |
0.653 |
|
1993 |
Trudeau LE, Castellucci VF. Sensitization of the gill and siphon withdrawal reflex of Aplysia: Multiple sites of change in the neuronal network Journal of Neurophysiology. 70: 1210-1220. PMID 8229169 DOI: 10.1152/Jn.1993.70.3.1210 |
0.627 |
|
1993 |
Baux G, Fossier P, Trudeau LE, Tauc L. Transmitter release and calcium currents at an Aplysia buccal ganglion synapse--II. Modulation by presynaptic receptors. Neuroscience. 53: 581-93. PMID 8098518 DOI: 10.1016/0306-4522(93)90223-3 |
0.579 |
|
1993 |
Trudeau LE, Castellucci VF. Excitatory amino acid neurotransmission at sensory-motor and interneuronal synapses of Aplysia californica Journal of Neurophysiology. 70: 1221-1230. PMID 7901346 DOI: 10.1152/Jn.1993.70.3.1221 |
0.679 |
|
1993 |
Trudeau LE, Baux G, Fossier P, Tauc L. Transmitter release and calcium currents at an Aplysia buccal ganglion synapse--I. Characterization. Neuroscience. 53: 571-80. PMID 7684115 DOI: 10.1016/0306-4522(93)90222-2 |
0.548 |
|
1992 |
Trudeau LE, Fossier P, Baux G, Tauc L. Xanthine derivatives IBMX and S-9977-2 potentiate transmission at an Aplysia central cholinergic synapse. Brain Research. 586: 78-85. PMID 1380883 DOI: 10.1016/0006-8993(92)91374-N |
0.603 |
|
1992 |
Fossier P, Baux G, Trudeau LE, Tauc L. Pre- and postsynaptic actions of nifedipine at an identified cholinergic central synapse of Aplysia. Pflã¼Gers Archiv : European Journal of Physiology. 422: 193-7. PMID 1362608 DOI: 10.1007/Bf00370420 |
0.604 |
|
1992 |
Baux G, Fossier P, Trudeau LE, Tauc L. Presynaptic receptors for FMRFamide, histamine and buccalin regulate acetylcholine release at a neuro-neuronal synapse of Aplysia by modulating N-type Ca2+ channels. Journal of Physiology, Paris. 86: 3-13. PMID 1343594 DOI: 10.1016/S0928-4257(05)80002-6 |
0.613 |
|
1992 |
Fossier P, Baux G, Trudeau LE, Tauc L. Involvement of Ca2+ uptake by a reticulum-like store in the control of transmitter release. Neuroscience. 50: 427-34. PMID 1331863 DOI: 10.1016/0306-4522(92)90434-4 |
0.563 |
|
1992 |
Trudeau LE, Castellucci VF. Contribution of polysynaptic pathways in the mediation and plasticity of Aplysia gill and siphon withdrawal reflex: Evidence for differential modulation Journal of Neuroscience. 12: 3838-3848. PMID 1328559 DOI: 10.1523/Jneurosci.12-10-03838.1992 |
0.625 |
|
Low-probability matches (unlikely to be authored by this person) |
2016 |
Giguère N, Trudeau L. La taille de l’axone est un facteur majeur influençant la dépense énergétique et la vulnérabilité des neurones dopaminergiques dans la maladie de Parkinson M S-Medecine Sciences. 32: 342-344. PMID 27137690 DOI: 10.1051/Medsci/20163204010 |
0.295 |
|
2006 |
Taherzadeh M, Fradette C, Bleau AM, Jomphe C, Trudeau LE, Du Souich P. The 21-aminosteroid U74389G prevents the down-regulation and decrease in activity of CYP1A1, 1A2 and 3A6 induced by an inflammatory reaction Biochemical Pharmacology. 71: 366-376. PMID 16332358 DOI: 10.1016/J.Bcp.2005.10.040 |
0.274 |
|
2013 |
Poliquin PO, Chen J, Cloutier M, Trudeau LE, Jolicoeur M. Metabolomics and In-Silico Analysis Reveal Critical Energy Deregulations in Animal Models of Parkinson's Disease Plos One. 8. PMID 23935941 DOI: 10.1371/Journal.Pone.0069146 |
0.272 |
|
2005 |
Drapeau J, El-Helou V, Clement R, Bel-Hadj S, Gosselin H, Trudeau LE, Villeneuve L, Calderone A. Nestin-expressing neural stem cells identified in the scar following myocardial infarction Journal of Cellular Physiology. 204: 51-62. PMID 15605421 DOI: 10.1002/Jcp.20264 |
0.271 |
|
2000 |
Trudeau LE. Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: Evidence for the involvement of multiple receptors Neuroscience. 97: 293-302. PMID 10799761 DOI: 10.1016/S0306-4522(99)00597-7 |
0.267 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2018 |
Giguère N, Burke Nanni S, Trudeau L. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease Frontiers in Neurology. 9. DOI: 10.3389/fneur.2018.00455 |
0.262 |
|
2020 |
Allain F, Delignat-Lavaud B, Beaudoin MP, Jacquemet V, Robinson TE, Trudeau LE, Samaha AN. Amphetamine maintenance therapy during intermittent cocaine self-administration in rats attenuates psychomotor and dopamine sensitization and reduces addiction-like behavior. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32682325 DOI: 10.1038/S41386-020-0773-1 |
0.258 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2005 |
Dal Bo G, Trudeau L. De la sérotonine dans les neurones à dopamine ? Une hypothèse intéressante sur le mode d’action des antidépresseurs, avec un sentiment de « déjà-vu »… MéDecine/Sciences. 21: 589-590. DOI: 10.1051/medsci/2005216-7589 |
0.246 |
|
2002 |
Galarneau A, Primeau M, Trudeau LE, Michnick SW. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. Nature Biotechnology. 20: 619-22. PMID 12042868 DOI: 10.1038/Nbt0602-619 |
0.223 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2008 |
Trudeau L. Antipsychotiques, dopamine et glutamate, une relation à établir Santé Mentale Au QuéBec. 32: 191-199. DOI: 10.7202/017805ar |
0.181 |
|
2006 |
St.-Gelais F, Jomphe C, Trudeau LE. The role of neurotensin in central nervous system pathophysiology: What is the evidence? Journal of Psychiatry and Neuroscience. 31: 229-245. PMID 16862241 |
0.166 |
|
2019 |
Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Morales MA, Trudeau LE, Svensson E. Editorial: Neuronal Co-transmission. Frontiers in Neural Circuits. 13: 19. PMID 30971899 DOI: 10.3389/Fncir.2019.00019 |
0.159 |
|
2019 |
Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Morales MA, Trudeau LE, Svensson E. Editorial: Neuronal Co-transmission. Frontiers in Neural Circuits. 13: 19. PMID 30971899 DOI: 10.3389/Fncir.2019.00019 |
0.159 |
|
2019 |
Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Morales MA, Trudeau LE, Svensson E. Editorial: Neuronal Co-transmission. Frontiers in Neural Circuits. 13: 19. PMID 30971899 DOI: 10.3389/Fncir.2019.00019 |
0.159 |
|
2019 |
Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Morales MA, Trudeau LE, Svensson E. Editorial: Neuronal Co-transmission. Frontiers in Neural Circuits. 13: 19. PMID 30971899 DOI: 10.3389/Fncir.2019.00019 |
0.159 |
|
2016 |
Matheoud D, Sugiura A, Bellemare-Pelletier A, Laplante A, Rondeau C, Chemali M, Fazel A, Bergeron JJ, Trudeau LE, Burelle Y, Gagnon E, McBride HM, Desjardins M. Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. PMID 27345367 DOI: 10.1016/J.Cell.2016.05.039 |
0.156 |
|
2016 |
Matheoud D, Sugiura A, Bellemare-Pelletier A, Laplante A, Rondeau C, Chemali M, Fazel A, Bergeron JJ, Trudeau LE, Burelle Y, Gagnon E, McBride HM, Desjardins M. Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. Cell. PMID 27345367 DOI: 10.1016/J.Cell.2016.05.039 |
0.156 |
|
2005 |
Stip E, Trudeau LE. Glycine and D-serine improve the negative symptoms of schizophrenia: Commentary Evidence-Based Mental Health. 8: 82. DOI: 10.1136/Ebmh.8.3.82 |
0.111 |
|
1992 |
Aragon CM, Trudeau LE, Amit Z. Effect of taurine on ethanol-induced changes in open-field locomotor activity. Psychopharmacology. 107: 337-40. PMID 1615135 DOI: 10.1007/Bf02245158 |
0.086 |
|
2008 |
Jomphe C, Gabriac M, Hale TM, Héroux L, Trudeau LE, Deblois D, Montell E, Vergés J, Du Souich P. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-κB in interleukin-1β-stimulated chondrocytes Basic and Clinical Pharmacology and Toxicology. 102: 59-65. PMID 17983423 DOI: 10.1111/J.1742-7843.2007.00158.X |
0.079 |
|
2004 |
Rompré PP, Stip E, Trudeau LE. Neurobiology of severe mental disorders: from cell to bedside 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal. Journal of Psychiatry & Neuroscience : Jpn. 29: 167-9. PMID 15173893 |
0.066 |
|
1991 |
Trudeau LE, Aragon CM, Amit Z. Involvement of endogenous opioid mechanisms in the interaction between stress and ethanol. Psychopharmacology. 103: 425-9. PMID 2057542 DOI: 10.1007/Bf02244299 |
0.065 |
|
2015 |
Trudeau L, Spoth R, Mason WA, Randall GK, Redmond C, Schainker L. Effects of Adolescent Universal Substance Misuse Preventive Interventions on Young Adult Depression Symptoms: Mediational Modeling. Journal of Abnormal Child Psychology. PMID 25795013 DOI: 10.1007/S10802-015-9995-9 |
0.063 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/Fnsyn.2012.00007 |
0.06 |
|
2012 |
Trudeau L. Obituary: Dr. Laurent Descarries (1939–2012) Frontiers in Synaptic Neuroscience. 4. DOI: 10.3389/Fnsyn.2012.00007 |
0.06 |
|
1990 |
Aragon CM, Trudeau LE, Amit Z. Stress-ethanol interaction: involvement of endogenous opioid mechanisms. Neuroscience and Biobehavioral Reviews. 14: 535-41. PMID 2287493 DOI: 10.1016/S0149-7634(05)80080-6 |
0.06 |
|
1990 |
Trudeau LE, Aragon CM, Amit Z. Effects of ethanol on locomotor depression and corticosterone release induced by restraint-stress: support for a stress-ethanol interaction. Pharmacology, Biochemistry, and Behavior. 36: 273-8. PMID 2356200 DOI: 10.1016/0091-3057(90)90403-5 |
0.059 |
|
2012 |
Trudeau L, Spoth R, Randall GK, Mason WA, Shin C. Internalizing symptoms: effects of a preventive intervention on developmental pathways from early adolescence to young adulthood. Journal of Youth and Adolescence. 41: 788-801. PMID 22160441 DOI: 10.1007/S10964-011-9735-6 |
0.053 |
|
2015 |
Spoth RL, Trudeau LS, Redmond C, Shin C, Greenberg MT, Feinberg ME, Hyun GH. PROSPER partnership delivery system: Effects on adolescent conduct problem behavior outcomes through 6.5 years past baseline. Journal of Adolescence. 45: 44-55. PMID 26356808 DOI: 10.1016/J.Adolescence.2015.08.008 |
0.051 |
|
2011 |
Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, ... ... Trudeau L, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. The Canadian Journal of Cardiology. 27: 415-433.e1-2. PMID 21801975 DOI: 10.1016/J.Cjca.2011.03.015 |
0.049 |
|
2012 |
Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, ... ... Trudeau L, et al. The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. The Canadian Journal of Cardiology. 28: 270-87. PMID 22595447 DOI: 10.1016/J.Cjca.2012.02.018 |
0.048 |
|
2014 |
Spoth R, Clair S, Trudeau L. Universal Family-Focused Intervention with Young Adolescents: Effects on Health-Risking Sexual Behaviors and STDs Among Young Adults Prevention Science. 15: 47-58. PMID 23408278 DOI: 10.1007/S11121-012-0321-2 |
0.046 |
|
2015 |
Spoth R, Trudeau L, Redmond C, Shin C. Replication RCT of early universal prevention effects on young adult substance misuse Journal of Consulting and Clinical Psychology. 82: 949-963. DOI: 10.1037.a0036840 |
0.038 |
|
2013 |
Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, ... ... Trudeau L, et al. The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. The Canadian Journal of Cardiology. 29: 528-42. PMID 23541660 DOI: 10.1016/j.cjca.2013.01.005 |
0.036 |
|
2013 |
Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, Feinberg M. Longitudinal effects of universal preventive intervention on prescription drug misuse: Three randomized controlled trials with late adolescents and young adults American Journal of Public Health. 103: 665-672. PMID 23409883 DOI: 10.2105/Ajph.2012.301209 |
0.036 |
|
2012 |
Spoth RL, Trudeau LS, Guyll M, Shin C. Benefits of universal intervention effects on a youth protective shield 10 years after baseline Journal of Adolescent Health. 50: 414-417. PMID 22443848 DOI: 10.1016/J.Jadohealth.2011.06.010 |
0.034 |
|
2013 |
Trudeau LC, Gagnon F. Suppression of multiple power line harmonic interference for low frequency signals Electronics Letters. 49: 114-116. DOI: 10.1049/El.2012.3901 |
0.034 |
|
2015 |
Johnson C, Raj TS, Trudeau L, Bacon SL, Padwal R, Webster J, Campbell N. The science of salt: a systematic review of clinical salt studies 2013 to 2014. Journal of Clinical Hypertension (Greenwich, Conn.). 17: 401-11. PMID 25789451 DOI: 10.1111/jch.12529 |
0.03 |
|
2014 |
Trudeau L. Central blood pressure as an index of antihypertensive control: Determinants and potential value Canadian Journal of Cardiology. 30: S23-S28. PMID 24750979 DOI: 10.1016/j.cjca.2014.03.010 |
0.028 |
|
2012 |
Trudeau L, Mason WA, Randall GK, Spoth R, Ralston E. Effects of parenting and deviant peers on early to mid-adolescent conduct problems. Journal of Abnormal Child Psychology. 40: 1249-64. PMID 22648200 DOI: 10.1007/S10802-012-9648-1 |
0.024 |
|
2014 |
Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. The Canadian Journal of Cardiology. 30: 485-501. PMID 24786438 DOI: 10.1016/j.cjca.2014.02.002 |
0.023 |
|
2010 |
Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, ... ... Trudeau L, et al. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. The Canadian Journal of Cardiology. 26: 249-58. PMID 20485689 DOI: 10.1016/S0828-282X(10)70379-2 |
0.018 |
|
2015 |
Dasgupta K, Padwal R, Poirier L, Quinn RR, Bacon S, Feldman RD, Hackam DG, Herman RJ, Khan N, Rabi DM, Ravani P, Tobe S, Rabkin S, Trudeau L, et al. Managing hypertension: evidence supporting the 2013/2014 recommendations of the Canadian Hypertension Education Program. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 187: 116-9. PMID 25316899 DOI: 10.1503/cmaj.131440 |
0.014 |
|
2011 |
Trudeau L, Coulombe S, Pigeon S. Pixel domain referenceless visual degradation detection and error concealment for mobile video Proceedings - International Conference On Image Processing, Icip. 2229-2232. DOI: 10.1109/ICIP.2011.6116080 |
0.013 |
|
2015 |
Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, ... ... Trudeau L, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. The Canadian Journal of Cardiology. 31: 549-68. PMID 25936483 DOI: 10.1016/J.Cjca.2015.02.016 |
0.012 |
|
2010 |
Kitchen J, Cherubini L, Trudeau L, Hodson J. Weeding out or developing capacity? Challenges for Aboriginal teacher education Alberta Journal of Educational Research. 56: 107-123. |
0.01 |
|
2015 |
Trudeau LJ. M-1 rail: A new foundation for growth in detroit built upon unprecedented partnerships Ite Journal (Institute of Transportation Engineers). 85: 31-34. |
0.01 |
|
2015 |
Padwal RS, Townsend RR, Trudeau L, Hamilton PG, Gelfer M. Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects. Journal of the American Society of Hypertension : Jash. 9: 123-9. PMID 25600420 DOI: 10.1016/j.jash.2014.11.004 |
0.01 |
|
2015 |
Trudeau L, Coulombe S, Desrosiers C. An adaptive search ordering for rate-constrained successive elimination algorithms Proceedings - International Conference On Image Processing, Icip. 2015: 207-211. DOI: 10.1109/ICIP.2015.7350789 |
0.01 |
|
2014 |
Trudeau L, Coulombe S, Desrosiers C. Rate distortion-based motion estimation search ordering for rate-constrained successive elimination algorithms 2014 Ieee International Conference On Image Processing, Icip 2014. 3175-3179. DOI: 10.1109/ICIP.2014.7025642 |
0.01 |
|
Hide low-probability matches. |